2017 American Society of Clinical Oncology Annual Meeting*

Download All
June 2-6, 2017; Chicago, Illinois
Sara Hurvitz, MD, FACP, and Kathy D. Miller, MD, review and share their expert perspectives on key breast cancer findings presented at the 2017 American Society of Clinical Oncology Annual Meeting.
Sara Hurvitz, MD, FACP
Kathy D. Miller, MD

Breast Cancer

Addition of the CDK4/6 inhibitor abemaciclib to fulvestrant reduced the risk of disease progression by 45%, with an acceptable tolerability profile.

Released: June 7, 2017

Significantly improved PFS and ORR observed with addition of lapatinib to trastuzumab plus investigator-selected aromatase inhibitor.

Released: June 6, 2017

Pembrolizumab monotherapy was well tolerated and active in a subset of pretreated metastatic TNBC patients, with promising preliminary survival results observed in patients with CR, PR, or SD.

Released: June 4, 2017

The addition of ipatasertib to paclitaxel improved PFS for patients with metastatic TNBC, with the greatest benefit observed in a prespecified subgroup analysis of patients with PIK3CA/AKT1/PTEN-altered tumors.

Released: June 4, 2017

Extended intermittent letrozole did not improve DFS or other efficacy outcomes compared with continuous dosing.

Released: June 8, 2017

TC noninferior to EC→T in patients with high-risk HER2-negative early BC with comparable 5-year DFS (90%), OS (95%), and reduced toxicity.

Released: June 12, 2017

The addition of pembrolizumab to neoadjuvant T → AC “graduated” I-SPY 2 for efficacy, approximately tripling the estimated pCR in TNBC and in HR+/HER2- EBC.

Released: June 9, 2017

Comparable pCR, less febrile neutropenia and LVEF decline with anthracycline-free vs anthracycline-containing neoadjuvant CT when paired with dual HER2 blockade.

Released: June 9, 2017

Addition of veliparib and carboplatin to neoadjuvant T → AC did not increase pCR rate over carboplatin plus T → AC alone.

Released: June 7, 2017

Review the latest developments in breast cancer care from ASCO 2017 with these expert insights from Sara Hurvitz, MD, FACP, and Kathy D. Miller, MD.

Sara Hurvitz, MD, FACP Kathy D. Miller, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 16, 2017 Expired: No longer available for credit

Study data showed significantly prolonged PFS and a lower rate of high-grade adverse events with olaparib monotherapy vs CT.

Released: June 8, 2017

Pertuzumab addition significantly reduced risk of recurrence vs current standard.

Released: June 5, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants by
Celgene Corporation
Halozyme Therapeutics
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.